Location: South Korea, , Seoul
Total raised: $42M
Investors 2
| Date | Name | Website |
| - | AJU IB Inv... | ajuib.co.k... |
| 06.02.2023 | Company K ... | kpartners.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.07.2025 | Series B | $42M | Hana Ventu... |
Mentions in press and media 3
| Date | Title | Description |
| 14.07.2025 | Illimis Therapeutics Raises $42M in Series B Funding | Illimis Therapeutics, a Seoul, South Korea-based biotechnology company which specializes in central nervous system and immune-related diseases, raised $42M in Series B funding. Backers included DSC Investment, Woori Venture Partners, Korea ... |
| 14.07.2025 | Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform | Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expan... |
| - | Illimis Therapeutics | “We translate cutting-edge science into innovative medicine” |